ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 126 filers reported holding ERASCA INC in Q2 2024. The put-call ratio across all filers is 45.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,180,136 | +78.9% | 500,058 | +56.1% | 0.00% | – |
Q1 2024 | $659,737 | -17.7% | 320,261 | -14.9% | 0.00% | – |
Q4 2023 | $801,280 | +114.6% | 376,188 | +98.4% | 0.00% | – |
Q3 2023 | $373,443 | +212.0% | 189,565 | +337.1% | 0.00% | – |
Q2 2023 | $119,707 | -50.5% | 43,372 | -46.0% | 0.00% | – |
Q1 2023 | $241,932 | +91195.1% | 80,376 | +30.5% | 0.00% | – |
Q4 2022 | $265 | – | 61,588 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARCH Venture Management, LLC | 11,055,554 | $95,078,000 | 13.59% |
AH Equity Partners Bio II, L.L.C. | 2,500,000 | $21,500,000 | 12.39% |
Cormorant Asset Management, LP | 10,505,554 | $90,348,000 | 6.94% |
EDBI Pte Ltd | 888,888 | $7,644,000 | 5.09% |
AH Equity Partners LSV II, L.L.C. | 312,500 | $2,688,000 | 1.94% |
PFM Health Sciences, LP | 4,791,406 | $41,206,000 | 1.54% |
Artal Group S.A. | 3,172,221 | $27,281,000 | 1.14% |
AH Equity Partners V, L.L.C. | 50,000 | $430,000 | 1.02% |
Orbimed Advisors | 1,667,693 | $14,342,000 | 0.23% |
EcoR1 Capital, LLC | 678,441 | $5,835,000 | 0.18% |